Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
NovoCure (NVCR) Stock Price & Analysis
1,340 Followers
NVCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.87 - $83.60
Previous Close$20.32
Volume2.03M
Average Volume (3M)1.34M
Market Cap
$2.19B
Enterprise Value$1.86B
Total Cash (Recent Filing)$921.25M
Total Debt (Recent Filing)$590.04M
Price to Earnings (P/E)-11.3
Beta1.77
Next Earnings
Jul 25, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding107,611,077
10 Day Avg. Volume1,301,560
30 Day Avg. Volume1,339,251
Standard Deviation0.19
R-Squared0.02
Alpha-0.00944
Financial Highlights & Ratios
Price to Book (P/B)5.34
Price to Sales (P/S)4.07
Price to Cash Flow (P/CF)-33.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.68
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda-8.32
Forecast
1Y Price Target
$26.25Price Target Upside24.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
NovoCure News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive top-line results from the Phase III METIS study evaluating Tumor Treating Fields in non-small cell lung cancer brain metastases.
Financial HealthNVCR disclosed cash and cash equivalents of $870.1M, along with a multi-tranche debt deal to fund future launches.
Product LaunchStrong continued launch in France, with about 40% penetration already, indicating potential market growth.
Bears Say
Clinical Trial OutcomesPreliminary analyses of key secondary endpoints did not demonstrate statistical significance, indicating uncertainty in the comprehensive efficacy of TTFields.
Financial PerformanceQ4 earnings per share (EPS) were negative, although better than consensus and estimates, indicating financial losses.
Regulatory RisksUncertain market opportunity and label for 2L NSCLC approvals, with the FDA review process potentially requiring additional time if more information or questions arise.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $10.87 and its highest was $83.60 in the past 12 months.
What is NovoCure Ltd’s market cap?
Currently, no data Available
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Jul 25, 2024 which is in 71 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on May 02, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.42 by $0.06.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -$0.41.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 107,611,080 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.42. Following the earnings report the stock price went up 11.381%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Among the largest hedge funds holding NovoCure Ltd’s share is Woodline Partners LP. It holds NovoCure Ltd’s shares valued at 6M.
---
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.25 (24.70% Upside)
$26.25 (24.70% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 62%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.91%
12-Months-Change
Fundamentals
Return on Equity
-48.70%
Trailing 12-Months
Asset Growth
-4.51%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q1 2024
0:00 / 0:00
---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$26.25
▲(24.70% Upside)
Technical Analysis
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+28.32%
reiterated a buy rating last month
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +28.32% per trade.
---